BAC’s CaptureSelect affinity purification and separation products are provided for the discovery, preclinical and clinical manufacturing of therapeutic proteins, including antibodies and antibody fragments.
The collaboration creates a HPLC columns pre-packed with CaptureSelect affinity ligands immobilized on POROS chromatography media.
The selectivity of these columns will support process analytical technology (PAT) for any biopharmaceutical manufacturing process.
BAC CEO Laurens Sierkstra said providing specificities and column formats will allow more researchers to access the benefits of CaptureSelect technology.
"Scientists will be able to use CaptureSelect ligands in formats that support QbD approaches for process development and monitoring," Sierkstra said.